Galectin Therapeutics
GALT
51 hedge funds and large institutions have $5.14M invested in Galectin Therapeutics in 2016 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 9 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
32% more call options, than puts
Call options by funds: $33K | Put options by funds: $25K
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
6% more capital invested
Capital invested by funds: $4.85M → $5.14M (+$288K)
2% more funds holding
Funds holding: 50 → 51 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$276K |
| 2 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$218K |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$38.1K |
| 4 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
+$34.8K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$29.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$602K |
| 2 |
AIG
American International Group
New York
|
-$500K |
| 3 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$54K |
| 4 |
CL
Croft-Leominster
Baltimore,
Maryland
|
-$42K |
| 5 |
Millennium Management
New York
|
-$29K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
51
Virtu KCG Holdings
New York
| – | -$15K | -10,437 | Closed |
|
52
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2.2K | -1,498 | -99% |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$70 | +48 | New |
|
54
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | +$293 | +200 | New |
|
GALT Hedge Fund Activity: Q2 2016 in Review
51 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2016, worth a combined $5.14M — up 5.9% from $4.85M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GALT positions and 9 closed out — a net gain of 1 holder — while 13 added to existing stakes and 7 trimmed.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $276K. The largest seller was Sabby Management, cutting an estimated $602K.
- 51 institutional investors held Galectin Therapeutics (GALT) as of Q2 2016, up from 50 in Q1 2016.
- Funds reported $5.14M of Galectin Therapeutics stock for Q2 2016, up 5.9% quarter-over-quarter.
- 10 funds opened new Galectin Therapeutics positions in Q2 2016 and 9 closed out, a net change of +1 holder.
- The largest Galectin Therapeutics buyer in Q2 2016 was Jacobs Levy Equity Management, an estimated $276K added.
- The largest Galectin Therapeutics seller in Q2 2016 was Sabby Management, an estimated $602K sold.
Based on aggregated 13F filings for Q2 2016.